ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
AstraZeneca PLC ADR AZN
News
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
AstraZeneca's Experimental Cancer Drug Misses Target in Pivotal Trial — Update
AstraZeneca's Breast Cancer Drug Missed Targets in Phase Three Trial
FLUMIST approved for self-administration in the US
MedImmune Receives FDA Approval for Self-Administered Flu Vaccine
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca Employees Detained in China Over Alleged Data, Drug-Import Violations — Update
AstraZeneca Employees Detained in China Over Data and Drug-Import Scrutiny
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
5 things you need to know about COVID, flu and RSV vaccines this fall
United States